araag2/HINT huggingface dataset:
Clinical trial NCT00709956 (phase 3, status: completed)
Conditions: pulmonary arterial hypertension
ICD codes: I27.21
Drugs: iloprost (5 µg), placebo
SMILES: [H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent prior to initiation of any study mandated procedure,

          -  Patients with symptomatic idiopathic, or familial pulmonary arterial hypertension or
             pulmonary hypertension associated with human immunodeficiency virus (HIV) or
             drugs/toxins in NYHA functional class II to IV.

          -  Women of childbearing potential must have a negative urine pregnancy test and must use
             an adequate method of contraception during the study and for 28 days after
             discontinuation of the study drug.

        Exclusion Criteria:

          -  Pulmonary arterial hypertension related to any condition other than those specified in
             the inclusion criteria,

          -  Pulmonary arterial hypertension associated with significant venous or capillary
             involvement (Pulmonary capillary wedge pressure (PCWP) > 15 mmHg),

          -  Known pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis,

          -  Moderate to severe obstructive lung disease: forced expiratory volume in 1
             second/forced vital capacity (FEV1/FVC) < 70% and FEV1 < 65% of predicted value after
             bronchodilator administration,

          -  Moderate to severe restrictive lung disease: total lung capacity (TLC) < 60% of
             predicted value,

          -  Pregnant or breast-feeding women,

          -  Systemic hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure
             > 100 mmHg on repeated measurement),

          -  Systolic blood pressure < 95 mmHg,

          -  Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C,

          -  Chronic renal insufficiency defined by serum creatinine > 2.5 mg/dL (221 μmol/L) or
             ongoing dialysis,

          -  Clinically relevant bleeding disorder or active bleeding,

          -  For those patients on monotherapy, any contraindication to bosentan, ambrisentan, or
             sildenafil, according to product label,

          -  Known hypersensitivity to iloprost or any of its excipients.
Clinical trial NCT00150371 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age 30 to 79 years old

          -  Triglyceride level 6.8 mmol/L at screening

          -  LDL-C of 5.7 mmol/L at screening

        Exclusion Criteria:

          -  Pregnant or lactating women, or women of childbearing potential not using an
             acceptable method of contraception. The latter are defined as: abstinence, surgical
             sterilization, oral contraceptives for at least 3 cycles, intrauterine device,
             implant, depot injection, or barrier method in conjunction with contraceptive foam or
             jelly.

          -  Subjects whose blood cholesterol levels are controlled (LDL-C targets) with statins
             other than atorvastatin

          -  Subjects receiving statin doses higher than the following: 10-40mg for simvastatin ,
             20-40mg for fluvastatin, pravastatin and lovastatin and 10-20 mg for rosuvastatin.
             Subjects already treated with atorvastatin at the time of screening are not eligible
             unless atorvastatin has been discontinued at least 2 months prior to screening

          -  Subjects receiving 2 or more lipid lowering agents are excluded (statins + resins or
             fibrates or niacin or fish oils)
Clinical trial NCT00308308 (phase 3, status: completed)
Conditions: diabetes, type i
ICD codes: E10.3521, E10.3522, E10.3523, E10.3529, E10.3531, E10.3532, E10.3533
Drugs: technosphere insulin, active comparator
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, CNC[C@H](O)C1=CC(O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of type 1 diabetes for at least 1 year

          -  Nonsmokers for prior 6 months

          -  BMI less than or equal to 35kg/m2

          -  HbA1c > or = 7% and < or = 11%

          -  Serum creatinine < or = 1.8 mg/dL in female subjects and < or = 2.0 mg/dL in male
             subjects

          -  FEV1 > or = 70% of predicted, DLco > or = 70% , TLC > or = 80% predicted

          -  Maintenance of a treatment regimen of insulin less than or equal to 1.4 iu/kg/day

          -  Urine cotinine < or = 100 ng/mL

        Exclusion Criteria:

          -  History of chronic obstructive pulmonary disease, asthma, any other clinically
             significant pulmonary disease confirmed by documented history, pulmonary function
             testing or radiologic findings

          -  Evidence of severe complications of diabetes

          -  Aminotransferase and/or alanine aminotransferase > than 3 times the upper limit of
             normal
Clinical trial NCT01179347 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: tiotropium respimat® inhaler, placebo respimat® inhaler
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Patients with a documented diagnosis of Cystic Fibrosis (CF) (positive sweat chloride
             >=60 mEq/liter, by pilocarpine iontophoresis) and/or a genotype with two identifiable
             mutations.

          2. Male or female patients (children less than 12 years and adolescents >12 years).

          3. Patients >=5 years of age must be able to perform acceptable spirometric maneuvers,
             according to the American Thoracic Society (ATS) standards.

          4. Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) >25% of predicted
             values.

          5. Pre-bronchodilator FEV1 at Visit 2 must be within 15% of FEV1 at Visit 1.

          6. No evidence of respiratory tract infection and no pulmonary exacerbation requiring use
             of intravenous/oral/inhaled antibiotics, or oral corticosteroids within 2 weeks of
             screening.

          7. The patient or the patient's legally acceptable representative must be able to give
             informed consent.

          8. Patients who are on a cycling TOBI® regimen must have completed at least 2 cycles
             every other month TOBI® administration prior to the screening visit.

          9. Patients who are on daily inhaled antibiotic use must be stabilized for at least 6
             weeks prior to Visit 1 (screening).

         10. Patients having previously participated in study 205.339 can also be selected.

        Exclusion criteria:

          1. Patients with a known hypersensitivity to study drug

          2. Patients who have participated in another study with an Investigational drug within
             one month preceding the screening visit.

          3. Patients who are currently participating in another trial. Observational studies are
             allowed. Permission should be obtained from sponsor of other study.

          4. Patients with known relevant substance abuse, including alcohol or drug abuse.

          5. Adolescent and adult female patients who are pregnant or lactating, including females
             who have a positive serum pregnancy test at screening.

          6. Female patients of child bearing potential who are not using a medically approved form
             of contraception.

          7. Clinically significant disease or medical condition other than CF or CF-related
             conditions that, in the opinion of the Investigator, would compromise the safety of
             the patient or the quality of the data. Patients with diabetes may participate if
             their disease is under good control prior to screening.
Clinical trial NCT00343655 (phase 3, status: terminated)
Conditions: cardiovascular diseases
ICD codes: A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30
Drugs: atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Reason stopped: 
    the study was terminated on june 22, 2007 for inability to enroll patients within an
    appropriate timeframe. there were no efficacy/safety concerns.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with measurable carotid plaque with lipid and are eligible for statin
             therapy.

        Exclusion Criteria:

          -  Subjects at higher risk for cardiovascular disease with a screen LDL-cholesterol
             greater than 120 mg/dL,

          -  Subjects currently on high dose statin, and

          -  Subjects with contraindications for MRI or statin therapy.
Clinical trial NCT00333359 (phase 3, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: xp13512 (gen)
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have successfully completed one of the following studies: XP052 (110963
             [NCT00298623]), XP053 (111460 [NCT00365352]), XP081 (111462 [NCT01332305]), and XP083
             (111463 [NCT01332318]).

        Exclusion Criteria:

          -  Subjects who, in the opinion of the Investigator, would be non-compliant with the
             study visit schedule, procedures, or medication administration.
Clinical trial NCT00634712 (phase 3, status: completed)
Conditions: congestive heart failure
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: candesartan, placebo
SMILES: CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 or above

          -  Congestive Heart Failure with symptoms for more than 4 weeks before starting study

          -  Provision of informed consent

        Exclusion Criteria:

          -  Current low blood pressure with symptoms

          -  Liver disease considered significant by the study doctor

          -  Pregnant or lactating females
Clinical trial NCT00002911 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: marimastat
SMILES: CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung
        cancer Stage IIIA/B disease No malignant pleural effusions Minimal residual disease after
        one or a combination of the following: Incomplete surgical resection i.e., macroscopic
        residual disease at completion of surgery Radical radiotherapy with no evidence of disease
        progression at entry Documented complete or partial tumor response following at least 2
        courses of cytotoxic chemotherapy No evidence of disease progression during or following
        prior therapy

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic:
        Absolute neutrophil count greater than 500/mm3 Platelet count greater than 50,000/mm3
        Hepatic: Bilirubin less than 2.0 times upper limit of normal (ULN) AST/ALT no greater than
        3.0 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: No acute illness
        within 1 week of start of study No other illness that would significantly interfere with
        study outcome No major medical illness that precludes prolonged marimastat administration
        No second malignancy within 5 years except: Adequately treated basal cell carcinoma of the
        skin In situ carcinoma of the cervix Not pregnant or nursing Medically approved method of
        contraception required of fertile women Willing and able to tolerate and comply with study
        requirements

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics No prior marimastat, batimastat, bleomycin, or busulphan No more than 1
        cytotoxic chemotherapy regimen for non-small cell lung cancer Endocrine therapy: Not
        specified Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics
        Other: At least 4 weeks since any investigational drug therapies
Clinical trial NCT00474045 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin detemir, nph insulin, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes treated with insulin for at least 12 months

          -  Planning to become pregnant and have a screening HbA1c (glycosylated haemoglobin)
             lesser than or equal to 9.0%, or

          -  Pregnant with an intrauterine singleton living foetus, 8-12 weeks pregnant when
             joining the trial and a HbA1c lesser than or equal to 8.0% when pregnancy is confirmed

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to the trial product(s) or related products

          -  Untreated hyperthyroidism or hypothyroidism

          -  Known or suspected abuse of alcohol or narcotics

          -  Cardiac problems

          -  Impaired kidney function

          -  History of severe hyperemesis gravidarum

          -  Treatment with in-vitro fertilisation or other medical infertility treatment

          -  Impaired liver function

          -  Uncontrolled hypertension

          -  Proliferative retinopathy or maculopathy requiring acute treatment

          -  Known to be HIV (human immunodeficiency virus) positive, Hepatitis B or Hepatitis C
             positive

          -  Any concomitant medication contraindicated in pregnancy
Clinical trial NCT00122850 (phase 3, status: completed)
Conditions: anxiety disorders
ICD codes: F41.1, F41.9, F40.9, F43.22, F41.0, F93.0, F12.980
Drugs: duloxetine, venlafaxine, placebo
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, [O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female outpatients at least 18 years of age, presenting with generalized
             anxiety disorder (GAD) based on the disease diagnostic criteria. Must suffer from GAD
             and not from an adjustment disorder or anxiety disorder not otherwise specified. The
             symptoms of GAD should not be situational in nature.

        Exclusion Criteria:

          -  Any current and primary DSM-IV Axis I diagnosis other than GAD, including:

               -  Patients diagnosed with major depressive disorder within the past 6 months; or

               -  Patients diagnosed with panic disorder, or post-traumatic stress disorder within
                  the past year; or

               -  Patients diagnosed with obsessive-compulsive disorder, bipolar affective
                  disorder, psychosis, factitious disorder, or somatoform disorders during their
                  lifetimes.

          -  The presence of an Axis II disorder or history of antisocial behavior, which, in the
             judgement of the investigator, would interfere with compliance with the study
             protocol.
Clinical trial NCT00076336 (phase 3, status: completed)
Conditions: hepatitis, hepatitis b, chronic, cirrhosis
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2, B18.0, B18.1, B18.2, B18.8, B18.9, K74.3, K74.4, K74.5, K74.60, K74.69, P78.81, K70.30
Drugs: telbivudine, lamivudine, placebo
SMILES: CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented decompensated chronic hepatitis B defined by all of the following: 1.
             Clinical history compatible with decompensated chronic hepatitis B related cirrhosis;
             2. Child-Turcotte-Pugh score > 7 points.

          -  Evidence of hepatic cirrhosis or portal hypertension.

        Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Patient is pregnant or breastfeeding.

          -  Patient is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV), or Human
             immunodeficiency virus (HIV).

          -  Patient previously received lamivudine, adefovir, or an investigational anti-hepatitis
             B virus (HBV) nucleoside or nucleotide analog at any time

          -  Patient has received interferon or other immunomodulatory treatment for HBV infection
             in the 12 months before Screening for this study.

        Other protocol-defined exclusion criteria may apply.
Clinical trial NCT00130975 (phase 3, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: candesartan
SMILES: CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with atrial fibrillation, diagnosed electrocardiographically, of more than 48
             hours duration in whom direct current (DC) cardioversion is planned.

        Exclusion Criteria:

          -  Patients with a history of known hypersensitivity or contraindication to any
             angiotensin II receptor blocker or any angiotensin-converting enzyme (ACE) inhibitor.

          -  Patients currently receiving an ACE inhibitor or angiotensin II antagonist because of
             heart failure or other strong indication.

          -  Patients currently receiving any antiarrhythmic medication including sotalol. Other
             beta-blockers will not be regarded as specific antiarrhythmic agents.

          -  Significant renal artery stenosis and any medical condition in which administration of
             a vasodilator is contraindicated; serum creatinine > 225 micromol/L; or serum
             potassium > 5.5 mmol/L; or serum sodium < 128 mmol/L.

          -  Patients with severe hepatic dysfunction.

          -  Life-limiting disease or substance abuse which may affect participation.

          -  Patients unwilling to participate.

          -  Patients who have previously undergone DC cardioversion for atrial fibrillation within
             the last month.

          -  Thyrotoxicosis.

          -  Patients with a systolic blood pressure of < 100 mm Hg.

          -  Hypertensive patients requiring intensified treatment prior to DC cardioversion.

          -  Pregnancy or lactation.
Clinical trial NCT00430950 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: olmesartan medoxomil (om)+ hydrochlorothiazide (hctz) tablets, olmesartan medoxomil (om)/ hydrochlorothiazide (hctz) 20mg/25mg
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female Europeans aged 18 years or older with moderate to severe HTN, defined
             as follows (conventional BP measurements)

        Exclusion Criteria:

          -  Female patients of childbearing potential pregnant, lactating or planning to become
             pregnant during the trial period.

          -  Patients with serious disorders which may limit the ability to evaluate the efficacy
             or safety of the study medication, including cerebrovascular, cardiovascular, renal,
             respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or
             oncological, neurological and psychiatric diseases.

          -  Patients having a history of the following within the last six months:

               -  myocardial infarction,

               -  unstable angina pectoris,

               -  percutaneous coronary intervention,

               -  severe heart failure,

               -  hypertensive encephalopathy, cerebrovascular accident (stroke) or

               -  transient ischaemic attack.

          -  Patients with clinically significant abnormal laboratory values at screening.

          -  Patients with secondary HTN.
Clinical trial NCT00124930 (phase 3, status: terminated)
Conditions: nausea, neoplasms
ICD codes: R11.0, R11.11, R11.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: olanzapine, haldol
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
Reason stopped: 
    study suspended due to low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  >18 years of age

          -  Significant nausea/vomiting

          -  Failed maxeran and domperidone

          -  Underlying treatment of causes has failed

          -  Adequate cognitive function

          -  Communicates well

        Exclusion Criteria:

          -  Partial/complete bowel obstruction

          -  Currently taking Haldol or olanzapine

          -  Has drug induced extrapyramidal symptoms

          -  Parkinson's disease

          -  Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus
Clinical trial NCT00255151 (phase 3, status: completed)
Conditions: esophagitis, reflux, esophagitis, peptic
ICD codes: K21.9, K21.00, K21.01, B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: dexlansoprazole mr, dexlansoprazole mr, placebo
SMILES: CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have successfully completed the Phase 3 Study T-EE04-084 (NCT00251693)
             or T-EE04-085 (NCT00251719); and have healed esophageal erosions proven by endoscopy.
             Complete healing was assessed for change in LA Esophagitis Classification grades A, B,
             C, or D to healed (defined as anything less than the criterion for Grade A). The
             subject was counted as healed if endoscopy findings did not meet the Grade A
             criterion.

        Exclusion Criteria:

          -  Use of prescription or nonprescription proton pump inhibitors (PPIs), histamine (H2)
             receptor antagonists, sucralfate, misoprostol, or prokinetics throughout the study

          -  Use of antacids (except for study supplied) throughout the study.

          -  Subjects using drugs with significant anticholinergic effects such as tricyclics who
             cannot stay on a stable dose throughout the study.

          -  Need for continuous anticoagulant therapy.